| B8 | HIV-1 drug resistance mutations in proviruses of early treated infants in Botswana | E-poster | Drug resistance testing |
| B8 | Integrase genotyping is highly effective on diverse HIV-1 non-B clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in Africa | E-poster | Drug resistance testing |
| A20 | GS-9822, a preclinical LEDGIN, displays a block-and-lock phenotype in cell culture | On-demand oral abstract session | Eliminating and silencing latency |
| A20 | Combination therapy with the broadly neutralizing antibody VRC07'523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+ T cell infection or reduce low-level viremia | Oral abstract session with live Q&A | Eliminating and silencing latency |
| A20 | XPB degradation by Spironolactone prevents HIV-1 reactivation from latency | E-poster | Eliminating and silencing latency |
| A20 | Dasatinib inhibits provirus reactivation in patients co-infected with HIV and HCV | E-poster | Eliminating and silencing latency |
| C3 | Comparisons of associations between incarceration and sexual risk behavior and STI/HIV among Black sexual minority men in Six U.S. cities (HPTN 061) | E-poster | Epidemiology of HIV in men who have sex with men |
| C3 | Geographical disparities in trends in national HIV diagnoses among gay, bisexual, and other men who have sex with men in Australia, 2014'2018 | E-poster | Epidemiology of HIV in men who have sex with men |
| C3 | Key correlates of lifetime HIV testing among young men who have sex with men in Seoul, South Korea | E-poster | Epidemiology of HIV in men who have sex with men |
| C3 | Geographical differences in uptake of HIV testing and PrEP among high risk gay and other men who have sex with men by gay population concentration in New South Wales, Australia | E-poster | Epidemiology of HIV in men who have sex with men |